vs

Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and UNITED STATES LIME & MINERALS INC (USLM). Click either name above to swap in a different company.

UNITED STATES LIME & MINERALS INC is the larger business by last-quarter revenue ($87.9M vs $60.1M, roughly 1.5× RHYTHM PHARMACEUTICALS, INC.). UNITED STATES LIME & MINERALS INC runs the higher net margin — 34.7% vs -92.6%, a 127.3% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs 9.8%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs 10.8%).

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

United States Lime & Minerals Inc is a leading US-based natural resources enterprise that produces high-calcium lime, dolomitic lime, limestone and related mineral products. Its core client segments cover infrastructure construction, steel manufacturing, agricultural soil amendment, environmental emission control and industrial processing, serving customers across North America.

RYTM vs USLM — Head-to-Head

Bigger by revenue
USLM
USLM
1.5× larger
USLM
$87.9M
$60.1M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+74.0% gap
RYTM
83.8%
9.8%
USLM
Higher net margin
USLM
USLM
127.3% more per $
USLM
34.7%
-92.6%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
43.8%
10.8%
USLM

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
RYTM
RYTM
USLM
USLM
Revenue
$60.1M
$87.9M
Net Profit
$-55.6M
$30.5M
Gross Margin
88.1%
48.0%
Operating Margin
-87.1%
41.0%
Net Margin
-92.6%
34.7%
Revenue YoY
83.8%
9.8%
Net Profit YoY
13.2%
EPS (diluted)
$-0.83
$1.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RYTM
RYTM
USLM
USLM
Q1 26
$60.1M
Q4 25
$57.3M
$87.9M
Q3 25
$51.3M
$102.0M
Q2 25
$48.5M
$91.5M
Q1 25
$32.7M
$91.3M
Q4 24
$41.8M
$80.1M
Q3 24
$33.3M
$89.4M
Q2 24
$29.1M
$76.5M
Net Profit
RYTM
RYTM
USLM
USLM
Q1 26
$-55.6M
Q4 25
$-47.5M
$30.5M
Q3 25
$-52.9M
$38.8M
Q2 25
$-46.6M
$30.8M
Q1 25
$-49.5M
$34.1M
Q4 24
$-43.3M
$27.0M
Q3 24
$-43.6M
$33.4M
Q2 24
$-32.3M
$26.1M
Gross Margin
RYTM
RYTM
USLM
USLM
Q1 26
88.1%
Q4 25
91.6%
48.0%
Q3 25
89.3%
51.2%
Q2 25
88.6%
45.8%
Q1 25
88.8%
50.6%
Q4 24
90.9%
44.3%
Q3 24
88.5%
48.2%
Q2 24
89.9%
45.5%
Operating Margin
RYTM
RYTM
USLM
USLM
Q1 26
-87.1%
Q4 25
-82.2%
41.0%
Q3 25
-102.6%
45.3%
Q2 25
-93.4%
39.0%
Q1 25
-143.7%
43.7%
Q4 24
-98.6%
38.8%
Q3 24
-132.0%
42.6%
Q2 24
-139.2%
39.1%
Net Margin
RYTM
RYTM
USLM
USLM
Q1 26
-92.6%
Q4 25
-83.0%
34.7%
Q3 25
-103.1%
38.0%
Q2 25
-96.1%
33.7%
Q1 25
-151.4%
37.4%
Q4 24
-103.6%
33.7%
Q3 24
-131.2%
37.3%
Q2 24
-110.9%
34.0%
EPS (diluted)
RYTM
RYTM
USLM
USLM
Q1 26
$-0.83
Q4 25
$-0.73
$1.06
Q3 25
$-0.82
$1.35
Q2 25
$-0.75
$1.07
Q1 25
$-0.81
$1.19
Q4 24
$-0.71
$-2.20
Q3 24
$-0.73
$1.16
Q2 24
$-0.55
$0.91

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RYTM
RYTM
USLM
USLM
Cash + ST InvestmentsLiquidity on hand
$340.6M
$371.1M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$122.9M
$630.8M
Total Assets
$442.3M
$681.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RYTM
RYTM
USLM
USLM
Q1 26
$340.6M
Q4 25
$388.9M
$371.1M
Q3 25
$416.1M
$349.5M
Q2 25
$291.0M
$319.9M
Q1 25
$314.5M
$300.6M
Q4 24
$320.6M
$278.0M
Q3 24
$298.4M
$255.0M
Q2 24
$319.1M
$222.5M
Total Debt
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Stockholders' Equity
RYTM
RYTM
USLM
USLM
Q1 26
$122.9M
Q4 25
$139.1M
$630.8M
Q3 25
$148.8M
$602.3M
Q2 25
$-11.9M
$563.3M
Q1 25
$18.9M
$532.2M
Q4 24
$21.7M
$497.7M
Q3 24
$11.2M
$474.2M
Q2 24
$39.3M
$441.1M
Total Assets
RYTM
RYTM
USLM
USLM
Q1 26
$442.3M
Q4 25
$480.2M
$681.0M
Q3 25
$506.9M
$652.8M
Q2 25
$372.7M
$607.4M
Q1 25
$386.7M
$585.3M
Q4 24
$392.3M
$543.2M
Q3 24
$363.6M
$521.8M
Q2 24
$381.8M
$484.2M
Debt / Equity
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RYTM
RYTM
USLM
USLM
Operating Cash FlowLast quarter
$45.6M
Free Cash FlowOCF − Capex
$25.7M
FCF MarginFCF / Revenue
29.2%
Capex IntensityCapex / Revenue
22.6%
Cash ConversionOCF / Net Profit
1.49×
TTM Free Cash FlowTrailing 4 quarters
$102.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
$-25.4M
$45.6M
Q3 25
$-26.6M
$45.9M
Q2 25
$-23.3M
$34.0M
Q1 25
$-40.4M
$39.4M
Q4 24
$-18.8M
$38.6M
Q3 24
$-25.2M
$39.0M
Q2 24
$-29.1M
$21.2M
Free Cash Flow
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
$25.7M
Q3 25
$31.3M
Q2 25
$20.8M
Q1 25
$24.6M
Q4 24
$27.6M
Q3 24
$33.9M
Q2 24
$16.8M
FCF Margin
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
29.2%
Q3 25
30.7%
Q2 25
22.7%
Q1 25
26.9%
Q4 24
34.4%
Q3 24
37.9%
Q2 24
21.9%
Capex Intensity
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
22.6%
Q3 25
14.4%
Q2 25
14.5%
Q1 25
16.3%
Q4 24
13.8%
Q3 24
5.8%
Q2 24
5.7%
Cash Conversion
RYTM
RYTM
USLM
USLM
Q1 26
Q4 25
1.49×
Q3 25
1.18×
Q2 25
1.10×
Q1 25
1.16×
Q4 24
1.43×
Q3 24
1.17×
Q2 24
0.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons